ANI Pharmaceuticals Inc (ANIP) Holdings Lifted by Argent Capital Management LLC
Argent Capital Management LLC boosted its stake in shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 33.3% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 40,635 shares of the specialty pharmaceutical company’s stock after purchasing an additional 10,150 shares during the quarter. Argent Capital Management LLC’s holdings in ANI Pharmaceuticals were worth $2,866,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently modified their holdings of the company. THB Asset Management lifted its stake in shares of ANI Pharmaceuticals by 1.1% during the first quarter. THB Asset Management now owns 25,431 shares of the specialty pharmaceutical company’s stock valued at $1,793,000 after buying an additional 275 shares during the period. Swiss National Bank raised its stake in ANI Pharmaceuticals by 3.2% during the first quarter. Swiss National Bank now owns 16,200 shares of the specialty pharmaceutical company’s stock worth $1,143,000 after purchasing an additional 500 shares during the period. Dimensional Fund Advisors LP raised its stake in ANI Pharmaceuticals by 3.2% during the first quarter. Dimensional Fund Advisors LP now owns 534,993 shares of the specialty pharmaceutical company’s stock worth $37,737,000 after purchasing an additional 16,566 shares during the period. Globeflex Capital L P raised its stake in ANI Pharmaceuticals by 179.8% during the first quarter. Globeflex Capital L P now owns 27,702 shares of the specialty pharmaceutical company’s stock worth $1,954,000 after purchasing an additional 17,802 shares during the period. Finally, BerganKDV Wealth Management LLC purchased a new position in ANI Pharmaceuticals during the first quarter worth approximately $141,000. Institutional investors own 63.92% of the company’s stock.
In other ANI Pharmaceuticals news, Director David Nash bought 1,445 shares of the business’s stock in a transaction dated Friday, May 24th. The shares were acquired at an average price of $68.76 per share, with a total value of $99,358.20. Following the purchase, the director now owns 5,236 shares in the company, valued at approximately $360,027.36. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Robert W. Schrepfer sold 4,651 shares of the firm’s stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $64.43, for a total transaction of $299,663.93. Following the completion of the transaction, the senior vice president now directly owns 53,484 shares in the company, valued at approximately $3,445,974.12. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 83,187 shares of company stock worth $5,639,795. 24.70% of the stock is currently owned by insiders.
ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.25. The company had revenue of $52.90 million for the quarter, compared to the consensus estimate of $50.57 million. ANI Pharmaceuticals had a net margin of 6.58% and a return on equity of 28.63%. ANI Pharmaceuticals’s revenue was up 13.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.32 earnings per share. On average, equities analysts predict that ANI Pharmaceuticals Inc will post 5.57 earnings per share for the current fiscal year.
A number of research firms have weighed in on ANIP. ValuEngine downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 15th. Zacks Investment Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $77.00 price target on the stock in a research note on Thursday, May 16th. Canaccord Genuity reaffirmed a “buy” rating and set a $90.00 price target (up previously from $80.00) on shares of ANI Pharmaceuticals in a research note on Monday, May 13th. BidaskClub raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 7th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $89.00 price target on shares of ANI Pharmaceuticals in a research note on Thursday, May 9th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. ANI Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $84.50.
TRADEMARK VIOLATION NOTICE: “ANI Pharmaceuticals Inc (ANIP) Holdings Lifted by Argent Capital Management LLC” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/ani-pharmaceuticals-inc-anip-holdings-lifted-by-argent-capital-management-llc/3030841.html.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Featured Article: Different Options Trading Strategies
Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals Inc (NASDAQ:ANIP).
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.